Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Vadim V. Markovtsov, PhD, Sothy Yi, Chi Young, Anne-Marie Duliege, MD MS, Esteban Masuda, PhD

Blood (2018) 132 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2018-99-113705

Published: 2018

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

David J. Kuter, MD DPhil, Richy Agajanian, MD, Donald M. Arnold, MD MSc, FRCPC, Michael Boxer, MD, Catherine Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Kerry A. Rogers, MD, Ann M Lowe, MD, Sandra Tong, MD, Hany Zayed, PhD, Anne-Marie Duliege, MD MS

Blood (2018) 132 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2018-99-110483

Published: 2018

Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 736.

https://doi.org/10.1182/blood-2018-99-110482

Published: 2018

Journal Articles

Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results

James B. Bussel, MD, Donald M Arnold, MD, Nichola Cooper, MA, MD MRCP, FRCPath, Alhossain A Khalafallah, MD, Michael Boxer, MD, Darla Liles, MD, Waleed Ghanima, MD PhD, Keith McCrae, MD, Hany Zayed, Benoit Cadieux, PhD, Anne-Marie Duliege, MDMS

Blood (2017) 130 (Supplement 1): 16.

https://doi.org/10.1182/blood.V130.Suppl_1.16.16

Published: 2017

Journal Articles

Correction of Anemia with Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), in Oncology Patients Receiving Chemotherapy.

Lisa M. Pickering, MBBS, BA, MRCP, Karel Cwiertka, MD, Jacek Jassem, Jira Petera, MD, Ruth Pettengell, MBchB, FRACP, PhD, Rodryg Ramlau, MD, PhD, Jiri Vorlicek, Rostislav Vyzula, MD, Anne-Marie Duliege, MD, MS, William Lang, MD, Richard B. Stead, MD, Peter G. Harper, LRCP, MRCS, MBBS

Blood (2007) 110 (11): 3666.

https://doi.org/10.1182/blood.V110.11.3666.3666

Published: 2007

Journal Articles

Hematide TM , a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy.

Lisa M. Pickering, MBBS, BA, MRCP, Karel Cwiertka, MD, Jacek Jassem, Jiri Petera, MD, Ruth Pettengell, MBchB, FRACP, PhD, Rodryg Ramlau, MD, PhD, Jiri Vorlicek, Rostislav Vyzula, MD, Corina Andresen, MD, Stephen Chang, PhD, MS, Anne-Marie Duliege, MD, MS, Robert Leong, MD, Richard Stead, MD, Peter G. Harper, LRCP MRCS, MB BS

Blood (2006) 108 (11): 1290.

https://doi.org/10.1182/blood.V108.11.1290.1290

Published: 2006

Journal Articles

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers

Richard B. Stead, John Lambert, Dawie Wessels, Julie S. Iwashita, Kerstin K. Leuther, Kathryn W. Woodburn, Peter J. Schatz, Douglas M. Okamoto, Robert Naso, Anne-Marie Duliege

Blood (2006) 108 (6): 1830–1834.

https://doi.org/10.1182/blood-2006-04-015818

Published: 2006

Journal Articles

Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).

Anne-Marie Duliege, MD, Iain Macdougall, MD, Neill Duncan, MD, Dawie Wessels, MD, Julie Iwashita, Pete Schatz, PhD, Robert Naso, PhD, Richard Stead, MD, John Lambert, MD

Blood (2005) 106 (11): 3532.

https://doi.org/10.1182/blood.V106.11.3532.3532

Published: 2005

NARROW

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results

Correction of Anemia with Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), in Oncology Patients Receiving Chemotherapy.

Hematide TM , a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy.

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers

Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only